Pfizer shares jump more than 7% on Wall Street, as Pharma Giant plans to lower drug prices in the US – details here

US pharmaceutical giant Pfizer Inc. shares have risen more than 7% during the Intraday session on Wall Street after US President Donald Trump announced that the company plans to lower drug prices in the United States. Trump said on Tuesday that Pfizer would lower the price of all prescription medicine in the Medicaid program for Low Income US Citizens and will sell new prescription drugs at a “most favorable country” price in exchange for tariff relief. US President Donald Trump has also announced that he expects other drugs to follow the Pfizer lead and reduce prices for drugs sold to US citizens. “The United States has finished subsidizing the healthcare of the rest of the world,” Trump said, and Albert Bourla and other drivers spoke to the media. Trump had earlier announced a 100% conditional rate for pharmaceutical imports to the United States, with effect from Wednesday, October 1, 2025. Pfizer share price Trend Pfizer Inc. The share price closed 6.69% higher at $ 25.45 after Tuesday’s Wall Street session, compared to $ 23.85 in the previous market. The company’s share has risen more than 7% during Tuesday’s Intraday session to its high level of $ 25.63. Shares of the Pharma Company have lost 26% over the past five years and traded 11.96% in the last one year. On a year-to-date (YTD) basis, the Pfizer shares were dropped by 4.25% in 2025. However, Pfizer shares gave US investors more than 2% on their investment in the last period of one month, and the shares trade more than 5% in the last five market sessions on Wall Street. According to the data collected from MarketWatch, the company’s shares hit their high level of 52 weeks at $ 30.43, while the low level of 52 weeks stood at $ 20.92. The company’s market cap (M-CAP) amounted to $ 135.6 billion on Tuesday, September 30, 2025. Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or brokerage companies, not coin. We advise investors to check with certified experts before making investment decisions.